Blood ozonization in patients with mild to moderate COVID-19 pneumonia: a single centre experience
- PDF / 1,988,504 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 56 Downloads / 220 Views
IM - ORIGINAL
Blood ozonization in patients with mild to moderate COVID‑19 pneumonia: a single centre experience Carlo Tascini1 · Giovanni Sermann2 · Alberto Pagotto1 · Emanuela Sozio1,3 · Chiara De Carlo1 · Alessandro Giacinta1 · Francesco Sbrana4 · Andrea Ripoli5 · Nadia Castaldo1 · Maria Merelli1 · Barbara Cadeo1 · Cristiana Macor2 · Amato De Monte2 Received: 13 July 2020 / Accepted: 14 October 2020 © Società Italiana di Medicina Interna (SIMI) 2020
Abstract The emerging outbreak of the coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread worldwide. We prescribed some promising medication to our patients with mild to moderate pneumonia due to SARS-CoV-2, however such drugs as chloroquine, hydrossichloroquine, azithromycin, antivirals (lopinavir/ritonavir, darunavir/cobicistat) and immunomodulating agents (steroids, tocilizumab) were not confirmed as effective against SARS-CoV2. We, therefore, started to use auto-hemotherapy treated with an oxygen/ozone (O2/ O3) gaseous mixture as adjuvant therapy. In Udine University Hospital (Italy) we performed a case–control study involving hospitalized adult patients with confirmed COVID-19 with mild to moderate pneumonia. Clinical presentations are based upon clinical phenotypes identified by the Italian Society of Emergency and Urgency Medicine (SIMEU—Società Italiana di Medicina di Emergenza-Urgenza) and patients that met criteria of phenotypes 2 to 4 were treated with best available therapy (BAT), with or without O 3-autohemotherapy. 60 patients were enrolled in the study: 30 patients treated with BAT and O 2/O3 mixture, as adjuvant therapy and 30 controls treated with BAT only. In the group treated with O 3-autohemotherapy plus BAT, patients were younger but with more severe clinical phenotypes. A decrease of SIMEU clinical phenotypes was observed (2.70 ± 0.67 vs. 2.35 ± 0.88, p = 0.002) in all patients during hospitalization but this clinical improvement was statistically significant only in O 3-treated patients (2.87 ± 0.78 vs. 2.27 ± 0.83, p 60 mmHg in ambient air) and/or pulmonary consolidation area. These patients need to be hospitalized because they can worsen quickly. • Phenotype 3: subjects with fever associated with moderate-severe respiratory insufficiency (at triage PO2
Data Loading...
